High and low cell counts of CD68+ cells in the tumor center (HR: 0.92; 95% CI: 0.46–1.81; p = 0.803), CD68+ cells in the invasion front (HR: 0.71; 95% CI: 0.37–1.38; p = 0.317), CD163+ cells in the tumor center (HR: 1.20; 95% CI: 0.62–2.34; p = 0.588), and CD163+ cells in the invasion front (HR: 0.98; 95% CI: 0.51–1.89; p = 0.955) showed no prognostic relevance in OS. The gene discussed is CD163; the disease is neoplasm.